产品
编 号：F018706
分子式：C18H14N4OS
分子量：334.39
分子式：C18H14N4OS
分子量：334.39
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1042735-18-1
产品详情
生物活性：
ABC1183 is an orally active selective dual GSK3 and CDK9 inhibitor. ABC1183 inhibits GSK3β, GSK3α and CDK9/cyclin T1 with the IC50 values of 657 nM, 327 nM and 321 nM, respectively. ABC1183 has anti-inflammatory and anti-tumor activities.
体内研究：
ABC1183 (oral gavage, 5 or 50 mg/kg) inhibits tumor proliferation through negative regulation of cell growth and pro-inflammatory signalling in male C57BL/6 mice.Animal Model:Male C57BL/6 mice with melanoma B16
Dosage:5 mg/kg
Administration:Oral gavage; 5 times per week; 22 days
Result:Reduced tumor size and no observed toxicity.Decreased the expression levels of GSK3 α /β, pSer21/9 and GS pSer641 but no change of total GS expression.
Animal Model:Male C57BL/6 mice infected crohn’s disease
Dosage:50 mg/kg
Administration:Oral gavage; everyday; 3 days
Result:Reduced TNF-α by 65%, IL-6 by 30% and IL-1β by 45%.
Animal Model:Male C57BL/6 mice with ulcerative colitis
Dosage:50 mg/kg
Administration:Oral gavage; once daily; 6 days
Result:Increased the expression of the anti-inflammatory factor IL-10, while decreasing the pro-inflammatory factor IL-6.
体外研究：
ABC1183 (3 μM, 24 h) can block cell cycle progression and thus affect cell proliferation.
ABC1183 is an orally active selective dual GSK3 and CDK9 inhibitor. ABC1183 inhibits GSK3β, GSK3α and CDK9/cyclin T1 with the IC50 values of 657 nM, 327 nM and 321 nM, respectively. ABC1183 has anti-inflammatory and anti-tumor activities.
体内研究：
ABC1183 (oral gavage, 5 or 50 mg/kg) inhibits tumor proliferation through negative regulation of cell growth and pro-inflammatory signalling in male C57BL/6 mice.Animal Model:Male C57BL/6 mice with melanoma B16
Dosage:5 mg/kg
Administration:Oral gavage; 5 times per week; 22 days
Result:Reduced tumor size and no observed toxicity.Decreased the expression levels of GSK3 α /β, pSer21/9 and GS pSer641 but no change of total GS expression.
Animal Model:Male C57BL/6 mice infected crohn’s disease
Dosage:50 mg/kg
Administration:Oral gavage; everyday; 3 days
Result:Reduced TNF-α by 65%, IL-6 by 30% and IL-1β by 45%.
Animal Model:Male C57BL/6 mice with ulcerative colitis
Dosage:50 mg/kg
Administration:Oral gavage; once daily; 6 days
Result:Increased the expression of the anti-inflammatory factor IL-10, while decreasing the pro-inflammatory factor IL-6.
体外研究：
ABC1183 (3 μM, 24 h) can block cell cycle progression and thus affect cell proliferation.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备